SKBR3

[1] SkBr3 cells were derived from a pleural effusion due to an adenocarcinoma originating in a 43-year-old caucasian female.

[1] The cell line over-expresses the HER2 gene product, which has been implicated in several breast cancer proliferation pathways.

They are known to grow in grape-like clusters with an invasive phenotype resembling that of the cells in vivo.

[3] SkBr3 cells have been used in studies seeking to overcome Herceptin treatment resistance to HER2-overexpressing breast cancers.

[4] The cell line has also been examined for applications in CRISPR/Cas9 gene editing,[5] antibody resistance in transfections, and HER2-based cancer therapies in context of microenvironment fluctuations.